1. Home
  2. IBRX vs HOMB Comparison

IBRX vs HOMB Comparison

Compare IBRX & HOMB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo ImmunityBio Inc.

IBRX

ImmunityBio Inc.

N/A

Current Price

$7.94

Market Cap

6.1B

Sector

Health Care

ML Signal

N/A

Logo Home BancShares Inc.

HOMB

Home BancShares Inc.

N/A

Current Price

$26.28

Market Cap

6.0B

Sector

Finance

ML Signal

N/A

Company Overview

Basic Information
Metric
IBRX
HOMB
Founded
2014
1998
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
Major Banks
Sector
Health Care
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
6.1B
6.0B
IPO Year
2015
2006

Fundamental Metrics

Financial Performance
Metric
IBRX
HOMB
Price
$7.94
$26.28
Analyst Decision
Strong Buy
Hold
Analyst Count
7
5
Target Price
$12.57
$32.40
AVG Volume (30 Days)
31.4M
1.3M
Earning Date
05-18-2026
04-14-2026
Dividend Yield
N/A
3.19%
EPS Growth
38.71
19.90
EPS
N/A
2.41
Revenue
$113,288,000.00
N/A
Revenue This Year
$88.57
$10.99
Revenue Next Year
$146.98
$5.14
P/E Ratio
N/A
$10.91
Revenue Growth
668.31
N/A
52 Week Low
$1.83
$24.23
52 Week High
$12.43
$30.83

Technical Indicators

Market Signals
Indicator
IBRX
HOMB
Relative Strength Index (RSI) 49.64 30.21
Support Level $2.27 $26.24
Resistance Level $8.28 $28.81
Average True Range (ATR) 1.03 0.75
MACD -0.33 -0.23
Stochastic Oscillator 3.33 15.17

Price Performance

Historical Comparison
IBRX
HOMB

About IBRX ImmunityBio Inc.

ImmunityBio Inc is an integrated clinical-stage biotechnology company discovering, developing, and commercializing next-generation immuno- and cellular therapies that bolster the natural immune system to drive and sustain an immune response. Its platforms for the development of biologic product candidates include (i) antibody-cytokine fusion proteins, (ii) DNA, RNA, and recombinant protein vaccines, and (iii) cell therapies. Its focus includes bladder, lung, and colorectal cancers and GBM and its product candidate Anktiva is an IL-15 superagonist antibody-cytokine fusion protein. It has two geographical segments: the United States and Europe. Key revenue is generated from the United States.

About HOMB Home BancShares Inc.

Home BancShares Inc is a bank holding company that operates through its wholly owned community bank subsidiary, Centennial Bank. The bank provides a broad range of commercial and retail banking, as well as related financial services, to a diverse customer base. Its customer base includes businesses, real estate developers and investors, individuals, and municipalities. The company's loan portfolio, while diversified, is typically between half and two thirds in commercial real estate loans. The company's plan emphasizes growth, both through strategic acquisitions and organically within its existing markets. The bank also emphasizes attracting experienced bankers, credit quality and a solid balance sheet. The bank's main source of net revenue is net interest income.

Share on Social Networks: